Physician profile
Sameer H Nagamia
NPI 1528252772
$14,235.32
in general payments reported to CMS, 2019-2025
40 companies · $2,252 in 2025
The $2,252 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,227 · 2020: $2,423 · 2021: $1,756 · 2022: $1,646 · 2023: $1,724 · 2024: $2,206 · 2025: $2,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,182.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,629.43 | 2019-2025 | Aveir, Mitraclip, Jot Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,412.36 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $1,080.73 | 2019-2024 | Farxiga |
| Pfizer INC. | $927.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.20 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $665.92 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $660.26 | 2019-2025 | Cds - Mct/Cem Monitoring, Farapulse, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $646.57 | 2019-2025 | |
| Amgen INC. | $553.46 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $482.85 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $459.89 | 2019-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $417.21 | 2024-2025 | Barostim Neo System |
| Amarin Pharma, INC. | $415.07 | 2019-2021 | |
| Esperion Therapeutics, INC. | $314.61 | 2020-2025 | Nexletol |
| Medtronic, INC. | $304.05 | 2021-2025 | Affera Mapping System, Reveal Linq |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $260.57 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $249.59 | 2019-2024 | |
| Atricure, INC. | $219.77 | 2022-2024 | |
| Astellas Pharma US INC | $208.47 | 2019-2021 | |
| Abiomed | $206.81 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $200.11 | 2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $196.69 | 2023-2025 | Opsumit, Uptravi |
| Biotronik INC. | $148.04 | 2020-2024 | Amvia Edge |
| Preventice Services, LLC | $113.80 | 2020-2021 | |
| Watermark Medical, INC. | $93.65 | 2020 | |
| Novo Nordisk INC | $67.56 | 2025 | Wegovy, Ozempic |
| Cardiva Medical, INC. | $66.39 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $59.06 | 2019 | |
| Alnylam Pharmaceuticals INC. | $58.29 | 2023-2025 | Onpattro |
| Philips North America LLC | $54.96 | 2020 | |
| Penumbra, INC. | $50.64 | 2022-2023 | Indigo System |
| Baxter Healthcare | $45.84 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $38.63 | 2020-2021 | |
| Cook Medical LLC | $37.67 | 2019-2020 | |
| G Medical Diagnostic Services, INC. | $32.27 | 2019 | |
| Medicomp INC | $31.60 | 2019-2021 | |
| Bardy Diagnostics, INC. | $31.00 | 2020-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $28.07 | 2022 | |
| Corcept Therapeutics | $26.93 | 2025 | Korlym |
| Lexicon Pharmaceuticals, INC. | $18.83 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Nagamia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.